Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML96: Risk-Adapted Postremission Therapy for Adult AML
NCT00180115Phase 4Completed
- Sponsor
- Technische Universität Dresden
- Start
- Feb 1996
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Technische Universität Dresden. Primary endpoints: Rate of Complete Remission, Overall Survival and 1 more. Started Feb 1996; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00180115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00180115.